Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23
March 20 2017 - 9:38PM
Business Wire
Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with
Daré Bioscience that the companies will hold a joint conference
call to discuss the definitive share purchase agreement under which
the stockholders of Daré Bioscience will become the majority owners
of Cerulean.
The conference call will take place at 9:00 a.m. ET on Thursday,
March 23, 2017. This call can be accessed by dialing 443-637-1284
or 844-831-3031 prior to the start of the call and referencing
conference ID 91378612.
The conference call also will be webcast live over
the Internet and can be accessed on the "Investors"
section of the Cerulean website, www.ceruleanrx.com. The
webcast will be archived on the Company's website until March 31,
2017.
About Daré Bioscience
Daré Bioscience is a clinical-stage pharmaceutical company
focusing on the development and commercialization of products for
women’s reproductive health. Daré is committed to advancing novel
clinical-stage candidates in women’s reproductive health to expand
options and improve outcomes. Product development in women’s
reproductive health is fragmented creating a potential opportunity
for Daré. Our goal is to fill the gap by taking products from
innovation through development – the Daré team is well-suited to
ensure these products advance and are one day commercially
available. The founders bring experience in global women’s
healthcare as well as success in prior ventures in funding,
achieving regulatory approvals, partnering, and launching a number
of products, including devices, therapeutics and diagnostics. For
more information on the company, please visit
www.darebioscience.com.
About Cerulean Pharma
Cerulean is a company focused on applying the Dynamic Tumor
Targeting™ Platform to create nanoparticle-drug conjugates (NDCs)
designed to selectively attack tumor cells, reduce toxicity by
sparing the body's normal cells, and enable therapeutic
combinations.
Additional Information about the Proposed Transaction and
Where to Find It
In connection with the proposed Daré transaction, Cerulean
intends to file relevant materials with the Securities and Exchange
Commission (the “SEC”), including a definitive proxy statement on
Schedule 14A (the “Proxy Statement”). The Proxy Statement will be
sent or given to the stockholders of Cerulean and will contain
important information about the proposed transaction and related
matters. BEFORE MAKING ANY VOTING DECISION, CERULEAN’S STOCKHOLDERS
ARE URGED TO READ THE PROXY STATEMENT AND THOSE OTHER MATERIALS
(INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY AND IN
THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE
PARTIES TO THE PROPOSED TRANSACTION. The Proxy Statement and other
relevant materials (when they become available), and any other
documents filed by Cerulean with the SEC, may be obtained free of
charge at the SEC’s website at www.sec.gov. In addition, security
holders will be able to obtain free copies of the proxy statement
by directing a written request to: Cerulean Pharma Inc., 35
Gatehouse Drive, Waltham, MA, Attention: Corporate Secretary.
Participants in the Solicitation
Cerulean, Daré, and each of their respective directors and
executive officers may be deemed to be participants in the
solicitation of proxies from the stockholders of Cerulean in
connection with the proposed transaction described herein.
Information regarding the interests of these directors and
executive officers in the proposed transaction described herein
will be included in the Proxy Statement described above.
Additional information regarding the directors and executive
officers of Cerulean is included in proxy statement for its 2016
Annual Meeting, which was filed with the SEC on April 28, 2016, and
is supplemented by other public filings made, and to be made, with
the SEC by Cerulean.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170320006337/en/
CeruleanChris Guiffre, 781-209-6450orDaréSabrina Martucci
Johnson, 858-769-9145
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Sep 2023 to Sep 2024